Mantovani G, Astara G, Lampis B, Bianchi A, Curreli L, Orrù W, Carta M G, Carpiniello B, Contu P, Rudas N
Department of Medical Oncology, University of Cagliari, Italy.
Support Care Cancer. 1996 Mar;4(2):129-40. doi: 10.1007/BF01845762.
Our study belongs to the clinical trials in which the health-related quality of life (HQL) evaluation constitutes the primary endpoint. It was carried out with the aim of comparing the impact of three different types of psychological intervention, namely a psychopharmacological treatment alone, the same treatment plus social support carried out by volunteers (SSV) and a third treatment modality including "structured psychotherapy" (autogenous training), on improving the HQL of elderly cancer patients undergoing antineoplastic therapy with symptoms of anxiety and/or depression related to their disease. The eight questionnaires used for HQL evaluation were generally self-rated and multidimensional but unidimensional models were also employed. Seventy-four patients aged over 65 years with either solid tumors in different sites or hematological malignancies, generally in advanced stages (III-IV), were enrolled in the study. Of these patients, 72 (42 men and 30 women, mean age 70.68 years, range 66-85) were evaluable. Our study highlighted the usefulness of the pharmacological therapy (alprazolam + sulpiride) and of other specific ancillary treatments in reducing the incidence of the main HQL-related side-effects of antineoplastic therapy and the superiority of an "integrated" strategy, based both on psychopharmacology and psychosocial interventions, such as SSV with or without structured psychotherapy. The one-way analysis of variance carried out by us did not allow us to draw definitive conclusions about which of the two integrated treatments was to be considered the treatment of choice, as they proved to be almost equally effective.
我们的研究属于以健康相关生活质量(HQL)评估为主要终点的临床试验。该研究旨在比较三种不同类型心理干预的效果,即单纯的心理药物治疗、同样的治疗加上志愿者提供的社会支持(SSV)以及第三种治疗方式,包括“结构化心理治疗”(自生训练),对改善正在接受抗肿瘤治疗且伴有与疾病相关的焦虑和/或抑郁症状的老年癌症患者的HQL的影响。用于HQL评估的八份问卷通常为自评且多维,但也采用了单维模型。研究纳入了74名65岁以上的患者,他们患有不同部位的实体瘤或血液系统恶性肿瘤,通常处于晚期(III - IV期)。其中72名患者(42名男性和30名女性,平均年龄70.68岁,范围66 - 85岁)可进行评估。我们的研究强调了药物治疗(阿普唑仑 + 舒必利)以及其他特定辅助治疗在降低抗肿瘤治疗主要HQL相关副作用发生率方面的有效性,以及基于心理药理学和心理社会干预(如有无结构化心理治疗的SSV)的“综合”策略的优越性。我们进行的单因素方差分析无法让我们就两种综合治疗中哪一种应被视为首选治疗得出明确结论,因为它们的效果几乎相同。